Shopping Cart
- Remove All
Your shopping cart is currently empty
Brepocitinib
🥰Excellent
Catalog No. TQ0010Cas No. 1883299-62-4
Alias PF-06700841
Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor with IC50 values of 17 nM and 23 nM, respectively, and also inhibits JAK2 and JAK3 with IC50 values of 77 nM and 6.49 μM.
Brepocitinib
🥰Excellent
Purity: 98%
Catalog No. TQ0010Alias PF-06700841Cas No. 1883299-62-4
Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor with IC50 values of 17 nM and 23 nM, respectively, and also inhibits JAK2 and JAK3 with IC50 values of 77 nM and 6.49 μM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $30 | In Stock | |
| 5 mg | $64 | In Stock | |
| 10 mg | $106 | In Stock | |
| 25 mg | $228 | In Stock | |
| 50 mg | $413 | In Stock | |
| 100 mg | $662 | In Stock | |
| 200 mg | $926 | In Stock | |
| 500 mg | $1,370 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $119 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Brepocitinib"
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $40
- $50
Size
QTY
CitedRuxolitinib phosphate Cited
Ruxolitinib (INCB-18424) phosphate, INCB018424 phosphate, INCB018424, INC424, INC 424 phosphate
T30431092939-17-7
Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Its selectivity for JAK1/2 is more than 130 times that of JAK3.
- $44
Size
QTY
CitedTofacitinib Citrate
Tofacitinib (CP-690550) Citrate, Tasocitinib citrate, CP-690550 citrate
T2398540737-29-9
Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).
- $32
Size
QTY
Ibrutinib Cited
PCI-32765
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
CitedDelgocitinib
JTE-052, Corectim（Delgocitinib）
T150961263774-59-9
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
- $172
Size
QTY
JAK-IN-10
T13571916741-98-5In house
JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.
- $79
Size
QTY
Fedratinib Cited
TG-101348, SAR 302503
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- $45
Size
QTY
CitedDeucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
Baricitinib Cited
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
- $43
Size
QTY
CitedRuxolitinib Cited
INCB018424, (R)-Ruxolitinib
T1829941678-49-5
Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.
- $53
Size
QTY
CitedGSK 3 Inhibitor IX Cited
MLS 2052, GSK 3 IX, BIO, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, 6-BIO
T1917667463-62-9
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
- $37
Size
QTY
CitedTofacitinib Cited
Tasocitinib, CP-690550
T6321477600-75-2
Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3/2/1 (IC50=1/20/112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.
- $30
Size
QTY
CitedSelect Batch
Purity:98%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor with IC50 values of 17 nM and 23 nM, respectively, and also inhibits JAK2 and JAK3 with IC50 values of 77 nM and 6.49 μM. |
| Targets&IC50 | JAK3:6.9 μM, TYK2:23 nM (cell free), JAK1:17 nM (cell free), JAK2:77 nM (cell free) |
| In vitro | PF-06700841 inhibits TYK2/JAK2 mediated IL-12/pSTAT4 and IL-23/pSTAT3 (human whole blood IC50s: 65/120 nM). PF-06700841 inhibits the JAK1/JAK3 driven γ-common chain cytokines, represented by IL-15/pStat5 and IL-21/pSTAT3 with reasonable potency (IC50s: 238/204 nM). PF-06700841 also has good potency against IL6/pStat1 in the CD3+ cellular subset (IC50: 81 nM), but lower inhibition of IL6/pSTAT3, again in the CD3+ cellular subset (IC50: 641 nM). PF-06700841 inhibits EPO/pSTAT5 (JAK2 homodimer) in HWB spiked with CD34+ progenitor cells (IC50: 577 nM). IL10/pSTAT3 (TYK2/JAK1) and IL27/pSTAT3 (JAK1/JAK2/TYK2) are also inhibited by PF-06700841 (IC50s: 305 nM/86 nM). |
| In vivo | PF-06700841 (3-30 mg/kg; p.o; for 7 consecutive days; female Lewis rats) treatment significantly reduces paw volume increase in a dose-dependent manner. The plasma concentrations in animals dosed with PF-06700841 at peak (30 min) and trough (24 h) time intervals post final dose respectively are as follows: 3 mg/kg, 3.54 μM, 0.0221 μM; 10 mg/kg, 10.95 μM, 0.06 μM; and 30 mg/kg, 23.89 μM, 0.06 μM. |
| Alias | PF-06700841 |
| Molecular Weight | 389.4 |
| Formula | C18H21F2N7O |
| Cas No. | 1883299-62-4 |
| Smiles | C(=O)(N1C2CN(CC1CC2)C3=NC(NC=4C=NN(C)C4)=NC=C3)[C@H]5C(F)(F)C5 |
| Relative Density. | 1.63 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 75 mg/mL (192.60 mM) DMSO: 75 mg/mL (192.60 mM) H2O: Insoluble | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Brepocitinib | purchase Brepocitinib | Brepocitinib cost | order Brepocitinib | Brepocitinib chemical structure | Brepocitinib in vivo | Brepocitinib in vitro | Brepocitinib formula | Brepocitinib molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.